Since PSMA is frequently overexpressed in the tumor microenvironment and tumor cells (stromal/tumor cells) of various cancers, and RGD can specifically detect integrins involved in the tumoral angiogenesis, it is expected that a combination of PSMA inhibitor and RGD peptides in one molecule labeled with 225Ac improves the response to the alpha-targeted radiotherapy attributed to the synergistic recognition of PSMA and integrins. The gene discussed is FOLH1; the disease is neoplasm.